Onco-Innovations Announces Private Placement

Executive Summary

• Onco‑Innovations Limited announced a non‑brokered private placement of up to 2,272,727 units at $0.88 per unit, targeting gross proceeds of up to $2 million.
• Each unit consists of one common share and half of a common‑share purchase warrant (full warrant exercisable at $1.10 per share for 36 months).
• The company will issue “Admin Fee Shares” equal to 1 % of the shares issued in the placement as compensation to an arm’s‑length third party, and may pay finder fees or issue additional warrants on the same terms.

Key Details

• Units Offered: Up to 2,272,727
• Price per Unit: $0.88
• Aggregate Gross Proceeds Target: Up to $2,000,000
• Unit Composition:
• 1 common share (“Share”)
• ½ of a common‑share purchase warrant (full warrant gives right to buy 1 Share at $1.10)
• Warrant Terms: Exercise price $1.10 per Share; exercisable for 36 months from issuance.
• Admin Fee Shares: Shares equal to 1 % of total shares issued in the private placement, issued to an arm’s‑length third party as a fee for assistance.
• Finder Fees/Warrants: Company may pay finder fees and/or issue additional warrants on the same terms to parties that introduce subscribers.
• Closing Conditions: Subject to receipt of all required regulatory and other approvals; securities subject to a hold period of four months + one day under applicable securities laws.
• Use of Proceeds: General corporate and working‑capital purposes, including advancement of operational and R&D objectives and investor‑relations activities.
• U.S. Offering Restrictions: Securities not registered under the U.S. Securities Act; cannot be offered or sold in the United States absent exemption or registration.

Notable Quotes

“We are pleased to announce this financing, which will provide essential capital to advance our oncology research and development programs.” – Thomas O'Shaughnessy, Chief Executive Officer

All forward‑looking statements are subject to risks and uncertainties detailed in the release.